Table 2. Clinical trails with targeted therapies, alone or in combination with chemotherapy, currently in development in CC.
| THERAPEUTIC REGIMEN | TARGET | PHASE | ClinicalTrials.gov Identifier |
|---|---|---|---|
| TRASTUZUMAB | HER2/neu | II | NCT00478140 |
| MK2206 | AKT | II | NCT01425879 |
| EVEROLIMUS | mTOR | II | NCT00973713 |
| REGORAFENIB | VEGFR1-3, c-KIT, TIE-2, PDGFR-β, C-Raf, B-Raf, p38 MAPK, FGFR-1, | II | NCT02115542 |
| GEMCITABINE + SORAFENIB | VEGFR-2/-3, PDGFR-β, B-Raf, C-Raf | II | NCT00661830 |
| GEMOX + SORAFENIB | VEGFR-2/-3, PDGFR-β, B-Raf, C-Raf | I/II |
NCT00955721 |
| GEMOX + BINIMETINIB | MEK1, MEK2 | I | NCT02105350 |
| PANITUMUMAB + GEMCITABINE/IRINOTECAN | EGFR | II | NCT00948935 |
| AFATINIB + GEMCITABINE/CISPLATIN | HER2/EGFR | I | NCT01679405 |
| BINIMETINIB + GEMCITABINE/CISPLATIN | MEK1, MEK2 | I/II | NCT01828034 |
| EVEROLIMUS + GEMCITABINE/CISPLATIN | mTOR | I | NCT00949949 |
| SELUMETINIB + GEMCITABINE/CISPLATIN | MEK1, MEK2 | I/II | NCT01242605 |
| CEDIRANIB + GEMCITABINE/CISPLATIN |
VEGFR-1, VEGFR-2, VEGFR-3 | II/III | NCT00939848 |
| CEDIRANIB MALEATE + FOLFOX 6 | VEGFR-1, VEGFR-2, VEGFR-3 | II | NCT01229111 |
| (GEMCITABINE, OXALIPLATIN, CAPECITABINE) + PANITUMUMAB OR BEVACIZUMAB | EGFR, VEGF | II | NCT01206049 |
Abbreviations: GEMOX, gemcitabine and oxaliplatin; nFOLFOX6, folinic acid-fluorouracil-oxaliplatin-6